Ctla4 (cytotoxic T-lymphocyte-associated protein 4) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Ctla4 (cytotoxic T-lymphocyte-associated protein 4) Rattus norvegicus
Symbol: Ctla4
Name: cytotoxic T-lymphocyte-associated protein 4
RGD ID: 61975
Description: Involved in negative regulation of T cell proliferation. Predicted to be located in several cellular components, including Golgi apparatus; clathrin-coated endocytic vesicle; and perinuclear region of cytoplasm. Predicted to be part of protein complex involved in cell adhesion. Predicted to be active in external side of plasma membrane. Used to study myocarditis. Human ortholog(s) of this gene implicated in several diseases, including carcinoma (multiple); graft-versus-host disease; hematologic cancer (multiple); kidney disease (multiple); and primary immunodeficiency disease (multiple). Orthologous to human CTLA4 (cytotoxic T-lymphocyte associated protein 4); PARTICIPATES IN autoimmune thyroiditis pathway; rheumatoid arthritis pathway; T cell receptor signaling pathway; INTERACTS WITH 3H-1,2-dithiole-3-thione; ammonium chloride; bisphenol A.
Type: protein-coding
Previously known as: Cd152; CD152 antigen; CTLA-4; cytotoxic T-lymphocyte protein 4; sCTLA4; soluble form; transmembrane form
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2962,318,874 - 62,325,978 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl962,319,312 - 62,324,963 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx970,821,431 - 70,826,972 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0975,937,041 - 75,942,584 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0974,255,613 - 74,261,154 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0967,699,397 - 67,706,068 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl967,699,379 - 67,706,065 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0967,509,236 - 67,515,681 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4959,495,773 - 59,501,300 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1959,642,754 - 59,648,282 (+)NCBI
Celera959,742,231 - 59,747,758 (+)NCBICelera
Cytogenetic Map9q32NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acute myeloid leukemia  (ISO)
adult T-cell leukemia/lymphoma  (ISO)
Alcoholic Liver Diseases  (ISO)
allergic rhinitis  (ISO)
alopecia areata  (ISO)
Alstrom syndrome  (ISO)
anogenital venereal wart  (ISO)
anti-basement membrane glomerulonephritis  (ISO)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis  (ISO)
asthma  (ISO)
atopic dermatitis  (ISO)
autoimmune hemolytic anemia  (ISO)
autoimmune hepatitis  (ISO)
Autoimmune Hypothyroidism  (ISO)
autoimmune lymphoproliferative syndrome type 2B  (ISO)
Autoimmune Lymphoproliferative Syndrome, Type V  (ISO)
autoimmune thyroiditis  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
basal cell carcinoma  (ISO)
Behcet's disease  (ISO)
breast cancer  (ISO)
Bronchial Hyperreactivity  (ISO)
celiac disease  (ISO)
Chronic Bronchitis  (ISO)
Chronic Hepatitis B  (ISO)
Chronic Hepatitis C  (ISO)
chronic obstructive pulmonary disease  (ISO)
common variable immunodeficiency 1  (ISO)
contact dermatitis  (ISO)
Cryptogenic Cirrhosis  (ISO)
Diabetic Nephropathies  (ISO)
end stage renal disease  (ISO)
Enterocolitis  (ISO)
Experimental Arthritis  (IMP,ISO)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Autoimmune Uveitis  (ISO)
Experimental Melanoma  (ISO)
genetic disease  (ISO)
graft-versus-host disease  (ISO)
granulomatosis with polyangiitis  (ISO)
Graves ophthalmopathy  (ISO)
Graves' disease  (ISO)
Hashimoto Disease  (ISO)
hepatitis A  (ISO)
hepatitis B  (ISO)
hepatocellular carcinoma  (ISO)
immunoglobulin alpha deficiency  (ISO)
Inflammation  (ISO)
iridocyclitis  (ISO)
juvenile rheumatoid arthritis  (ISO)
kidney disease  (ISO)
Kidney Reperfusion Injury  (ISO)
latent autoimmune diabetes in adults  (ISO)
lung disease  (ISO)
lupus nephritis  (ISO)
Lymphadenopathy  (ISO)
Lymphatic Metastasis  (ISO)
malaria  (ISO)
melanoma  (ISO)
monoclonal gammopathy of uncertain significance  (ISO)
multiple myeloma  (ISO)
multiple sclerosis  (ISO)
myocardial infarction  (ISO)
myocarditis  (IMP)
Neoplasm Metastasis  (ISO)
Neurodevelopmental Disorders  (ISO)
non-Hodgkin lymphoma  (ISO)
oral submucous fibrosis  (ISO)
peripheral nervous system disease  (ISO)
primary biliary cholangitis  (ISO)
primary cutaneous T-cell non-Hodgkin lymphoma  (ISO)
primary immunodeficiency disease  (ISO)
primary pulmonary hypertension  (ISO)
Primary Pulmonary Hypertension, 1  (ISO)
Prostatic Neoplasms  (ISO)
psoriasis  (ISO)
Pulmonary Arterial Hypertension  (ISO)
renal cell carcinoma  (ISO)
rheumatoid arthritis  (ISO)
rhinitis  (ISO)
sarcoidosis  (ISO)
silicosis  (ISO)
Sjogren's syndrome  (ISO)
Splenomegaly  (ISO)
squamous cell carcinoma  (ISO)
systemic lupus erythematosus  (ISO)
Transplant Rejection  (IMP,ISO)
tropical spastic paraparesis  (ISO)
type 1 diabetes mellitus  (ISO)
type 1 diabetes mellitus 12  (ISO)
urinary schistosomiasis  (ISO)
vitiligo  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function
protein binding  (IPI,ISO)

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Prevention of experimental autoimmune myocarditis by hydrodynamics-based naked plasmid DNA encoding CTLA4-Ig gene delivery. Abe S, etal., J Card Fail. 2005 Sep;11(7):557-64.
2. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. Abrams JR, etal., J Exp Med. 2000 Sep 4;192(5):681-94.
3. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. Agarwal K, etal., J Hepatol. 2000 Apr;32(4):538-41.
4. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. Aiba Y, etal., J Gastroenterol. 2011 Oct;46(10):1203-12. doi: 10.1007/s00535-011-0417-7. Epub 2011 May 19.
5. Promoter region -318 C/ T and -1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in North Indians. Baniasadi V, etal., Tissue Antigens. 2006 May;67(5):383-9.
6. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. Beck KE, etal., J Clin Oncol. 2006 May 20;24(15):2283-9. doi: 10.1200/JCO.2005.04.5716.
7. Functional polymorphism in CTLA4 gene influences the response to therapy with inhaled corticosteroids in Slovenian children with atopic asthma. Berce V and Potocnik U, Biomarkers. 2010 Mar;15(2):158-66.
8. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Beyer M, etal., Blood. 2005 Sep 15;106(6):2018-25. Epub 2005 May 24.
9. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blazar BR, etal., Blood. 1994 Jun 15;83(12):3815-25.
10. CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases. Blomhoff A, etal., Pigment Cell Res. 2005 Feb;18(1):55-8.
11. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Bolstad AI, etal., Arthritis Rheum. 2003 Jan;48(1):174-85.
12. CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Braun J, etal., Tissue Antigens. 1998 May;51(5):563-6.
13. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Chandraker A, etal., Kidney Int. 1997 Dec;52(6):1678-84.
14. CTLA-4 is important in maintaining long-term survival of cardiac allografts. Chandraker A, etal., Transplantation. 2005 Apr 27;79(8):897-903.
15. Cytotoxic T lymphocyte antigen-4 gene polymorphisms and susceptibility to type 1 autoimmune hepatitis in the Tunisian population. Chaouali M, etal., Genes Dis. 2017 Dec 30;5(3):256-262. doi: 10.1016/j.gendis.2017.12.006. eCollection 2018 Sep.
16. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. Chikuma S, etal., J Exp Med 2003 Jan 6;197(1):129-35.
17. Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A. Cho H, etal., Gut Liver. 2016 Mar;10(2):288-94. doi: 10.5009/gnl14368.
18. CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Cosentino A, etal., Ann N Y Acad Sci. 2002 Apr;958:337-40.
19. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Cozar JM, etal., Hum Immunol. 2007 Aug;68(8):698-704. Epub 2007 Jun 6.
20. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Cunnane G, etal., Arthritis Rheum. 2004 May;50(5):1539-48.
21. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Daroszewski J, etal., Eur J Endocrinol. 2009 Nov;161(5):787-93. doi: 10.1530/EJE-09-0600. Epub 2009 Sep 4.
22. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Demaria S, etal., Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34.
23. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Deurloo DT, etal., Am J Respir Cell Mol Biol. 2001 Dec;25(6):751-60.
24. CD28/CTLA4 double deficient mice demonstrate crucial role for B7 co-stimulation in the induction of allergic lower airways disease. Deurloo DT, etal., Clin Exp Allergy. 2003 Sep;33(9):1297-304.
25. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Djilali-Saiah I, etal., Gut 1998 Aug;43(2):187-9.
26. CD4+/CD25+ cells in systemic inflammation in COPD. Domagala-Kulawik J, etal., Scand J Immunol. 2011 Jan;73(1):59-65. doi: 10.1111/j.1365-3083.2010.02474.x.
27. Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis. Donaldson P, etal., Clin Gastroenterol Hepatol. 2007 Jun;5(6):755-60. doi: 10.1016/j.cgh.2007.02.012. Epub 2007 May 7.
28. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. Donner H, etal., J Clin Endocrinol Metab 1997 Dec;82(12):4130-2.
29. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. Downie-Doyle S, etal., Arthritis Rheum. 2006 Aug;54(8):2434-40.
30. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Dwivedi M, etal., Pigment Cell Melanoma Res. 2011 Aug;24(4):737-40. doi: 10.1111/j.1755-148X.2011.00892.x.
31. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Erfani N, etal., Cancer Invest. 2010 Oct;28(8):828-32. doi: 10.3109/07357901003630934.
32. Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese. Furugaki K, etal., J Hum Genet. 2004;49(3):166-8. Epub 2004 Feb 20.
33. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. Gallon L, etal., J Immunol. 1997 Nov 1;159(9):4212-6.
34. Polymorphisms in cytotoxic T lymphocyte associated antigen-4 influence the rate of acute rejection after renal transplantation in 167 Chinese recipients. Gao JW, etal., Transpl Immunol. 2012 Jun;26(4):207-11. doi: 10.1016/j.trim.2012.02.005. Epub 2012 Mar 6.
35. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
36. Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis. Giscombe R, etal., J Rheumatol. 2002 May;29(5):950-3.
37. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
38. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Greve B, etal., Mult Scler. 2008 Mar;14(2):153-8. Epub 2007 Oct 17.
39. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation. Guo L, etal., Transpl Immunol. 2003 Oct-Nov;12(1):41-8.
40. The shared CTLA4-ICOS risk locus in celiac disease, IgA deficiency and common variable immunodeficiency. Haimila K, etal., Genes Immun. 2009 Mar;10(2):151-61. doi: 10.1038/gene.2008.89. Epub 2008 Nov 20.
41. The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Han SZ, etal., Int J Immunogenet. 2006 Aug;33(4):281-7.
42. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) exon 1 polymorphism affects lymphocyte profiles in bronchoalveolar lavage of patients with sarcoidosis. Handa T, etal., Sarcoidosis Vasc Diffuse Lung Dis. 2003 Oct;20(3):190-6.
43. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Harbo HF, etal., Tissue Antigens 1999 Jan;53(1):106-10.
44. No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Heward JM, etal., Clin Endocrinol (Oxf). 1998 Sep;49(3):331-4.
45. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. Heward JM, etal., J Clin Endocrinol Metab. 1999 Jul;84(7):2398-401.
46. Targeting of CD25 and glucocorticoid-induced TNF receptor family-related gene-expressing T cells differentially modulates asthma risk in offspring of asthmatic and normal mother mice. Hubeau C, etal., J Immunol. 2007 Feb 1;178(3):1477-87.
47. A pilot study on cytotoxic T lymphocyte-4 gene polymorphisms in urinary schistosomiasis. Idris ZM, etal., Genet Test Mol Biomarkers. 2012 Jun;16(6):488-92. doi: 10.1089/gtmb.2011.0209. Epub 2012 Jan 30.
48. The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. Ikegami H, etal., J Clin Endocrinol Metab. 2006 Mar;91(3):1087-92. Epub 2005 Dec 13.
49. Distribution of CTLA-4 polymorphisms in allergic asthma. Jasek M, etal., Int Arch Allergy Immunol. 2006;141(3):223-9. Epub 2006 Aug 22.
50. Polymorphisms within the CTLA4 gene are associated with infant atopic dermatitis. Jones G, etal., Br J Dermatol. 2006 Mar;154(3):467-71.
51. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Kamesh L, etal., Rheumatology (Oxford). 2009 Dec;48(12):1502-5. doi: 10.1093/rheumatology/kep280. Epub 2009 Oct 8.
52. The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Karabon L, etal., Immunology. 2009 Sep;128(1 Suppl):e787-96. doi: 10.1111/j.1365-2567.2009.03083.x. Epub 2009 Feb 17.
53. Differences in the contribution of the CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients. Kawasaki E, etal., Diabetes Care. 2008 Aug;31(8):1608-10. Epub 2008 Apr 28.
54. Effects of inhaled fluticasone propionate on CTLA-4-positive CD4+CD25+ cells in induced sputum in mild asthmatics. Kawayama T, etal., Respirology. 2008 Nov;13(7):1000-1007.
55. Polymorphisms of the CTLA4 gene and kidney transplant rejection in Korean patients. Kim HJ, etal., Transpl Immunol. 2010 Oct;24(1):40-4. doi: 10.1016/j.trim.2010.10.001. Epub 2010 Oct 19.
56. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. Knoerzer DB, etal., J Clin Invest. 1995 Aug;96(2):987-93.
57. Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. Kurup SP, etal., Nat Med. 2017 Oct;23(10):1220-1225. doi: 10.1038/nm.4395. Epub 2017 Sep 11.
58. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Kwon ED, etal., Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103.
59. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Kwon ED, etal., Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9.
60. PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. LaBerge GS, etal., J Invest Dermatol. 2008 Jul;128(7):1757-62. doi: 10.1038/sj.jid.5701233. Epub 2008 Jan 17.
61. Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury. Lai LW, etal., Kidney Int. 2012 May;81(10):983-92. doi: 10.1038/ki.2011.412. Epub 2011 Dec 21.
62. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth. Lan KH, etal., Biochem Biophys Res Commun. 2013 Oct 18;440(2):222-8. doi: 10.1016/j.bbrc.2013.09.031. Epub 2013 Sep 13.
63. Association of asthma severity and bronchial hyperresponsiveness with a polymorphism in the cytotoxic T-lymphocyte antigen-4 gene. Lee SY, etal., Chest. 2002 Jul;122(1):171-6.
64. Association between cytotoxic T-lymphocyte antigen 4 gene polymorphisms and primary biliary cirrhosis in Chinese population: data from a multicenter study. Li Q, etal., J Gastroenterol Hepatol. 2013 Aug;28(8):1397-402. doi: 10.1111/jgh.12165.
65. CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice. Liu F, etal., PLoS One. 2010 Nov 3;5(11):e15404.
66. CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. Liu Y, etal., Hum Immunol. 2010 Nov;71(11):1141-6. Epub 2010 Aug 21.
67. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Marron MP, etal., Hum Mol Genet 1997 Aug;6(8):1275-82.
68. Cytotoxic T-lymphocyte antigen 4 (CTLA4) +49AG and CT60 gene polymorphisms in Alopecia Areata: a case-control association study in the Italian population. Megiorni F, etal., Arch Dermatol Res. 2013 Sep;305(7):665-70. doi: 10.1007/s00403-013-1348-3. Epub 2013 Apr 9.
69. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
70. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. Mohammad Alizadeh AH, etal., World J Gastroenterol. 2006 Jan 28;12(4):630-5.
71. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Monne M, etal., Am J Hematol. 2004 May;76(1):14-8.
72. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Motta M, etal., Leukemia. 2005 Oct;19(10):1788-93.
73. CTLA-4 polymorphisms in allergy and asthma and the TH1/ TH2 paradigm. Munthe-Kaas MC, etal., J Allergy Clin Immunol. 2004 Aug;114(2):280-7.
74. T cell pathways involving CTLA4 contribute to a model of acute lung injury. Nakajima T, etal., J Immunol. 2010 May 15;184(10):5835-41. Epub 2010 Apr 12.
75. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
76. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Nishikawa K, etal., Eur J Immunol. 1994 Jun;24(6):1249-54.
77. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Nistico L, etal., Hum Mol Genet. 1996 Jul;5(7):1075-80.
78. The role of CTLA-4 in murine contact hypersensitivity. Nuriya S, etal., J Invest Dermatol. 2001 May;116(5):764-8.
79. A native soluble form of CTLA-4. Oaks MK, etal., Cell Immunol 2000 May 1;201(2):144-53.
80. Nucleotide sequence of the ACI rat CTLA-4 molecule. Oaks MK, etal., Immunogenetics 1996;43(3):173-4.
81. Nucleotide sequence of the ACI rat CTLA-4 molecule. Oaks MK, etal., Immunogenetics 1996;43(3):173-4.
82. SNP analysis of genes implicated in T cell proliferation in primary biliary cirrhosis. Oertelt S, etal., Clin Dev Immunol. 2005 Dec;12(4):259-63. doi: 10.1080/17402520500317859.
83. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
84. CTLA4Ig alters the course of autoimmune disease development in Lyn-/- mice. Oracki SA, etal., J Immunol. 2010 Jan 15;184(2):757-63. doi: 10.4049/jimmunol.0804349. Epub 2009 Dec 4.
85. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease. Park KS, etal., Tissue Antigens. 2009 Sep;74(3):222-7. doi: 10.1111/j.1399-0039.2009.01303.x. Epub 2009 Jun 25.
86. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Pavkovic M, etal., Am J Hematol. 2003 Feb;72(2):147-9.
87. Association between IL4 (-590), ACE (I)/(D), CCR5 (Delta32), CTLA4 (+49) and IL1-RN (VNTR in intron 2) gene polymorphisms and vitiligo. Pehlivan S, etal., Eur J Dermatol. 2009 Mar-Apr;19(2):126-8. doi: 10.1684/ejd.2008.0578. Epub 2009 Jan 7.
88. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Perez-Garcia A, etal., Leukemia. 2009 Mar;23(3):486-91. doi: 10.1038/leu.2008.339. Epub 2008 Dec 18.
89. CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Petrone A, etal., Thyroid. 2005 Mar;15(3):232-8.
90. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
91. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. Queirolo P, etal., Cancer Invest. 2013 Jun;31(5):336-45. doi: 10.3109/07357907.2013.793699. Epub 2013 May 3.
92. In vivo fluctuation of Tax, Foxp3, CTLA-4, and GITR mRNA expression in CD4(+)CD25(+) T cells of patients with human T-lymphotropic virus type 1-associated myelopathy. Ramirez E, etal., Braz J Med Biol Res. 2010 Nov;43(11):1109-15. doi: 10.1590/s0100-879x2010007500107. Epub 2010 Oct 8.
93. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Reynolds J, etal., J Clin Invest. 2000 Mar;105(5):643-51.
94. GOA pipeline RGD automated data pipeline
95. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
96. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
97. Comprehensive gene review and curation RGD comprehensive gene curation
98. [CD28 and CTLA-4 costimulatory molecules expression on T lymphocytes and NK cells in nonallergic bronchial asthma]. Rutkowski R, etal., Pol Merkur Lekarski. 2006 Feb;20(116):139-44.
99. Topical CTLA4-Ig suppresses ongoing mucosal immune response in presensitized murine model of allergic rhinitis. Sato J, etal., Int Arch Allergy Immunol. 1999 Jul;119(3):197-204.
100. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Schott E, etal., Eur J Gastroenterol Hepatol. 2007 Nov;19(11):947-51. doi: 10.1097/MEG.0b013e3282efa240.
101. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Schubert D, etal., Nat Med. 2014 Dec;20(12):1410-6. doi: 10.1038/nm.3746. Epub 2014 Oct 20.
102. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Shao H, etal., Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2016-21.
103. Soluble CTLA-4 in sera of patients with bronchial asthma. Shi HZ, etal., J Asthma. 2005 Mar;42(2):133-9.
104. Mechanistic investigation of immunosuppression in patients with condyloma acuminata. Shi YJ, etal., Mol Med Rep. 2013 Aug;8(2):480-6. doi: 10.3892/mmr.2013.1511. Epub 2013 Jun 6.
105. Prevention of acute lung allograft rejection in rat by CTLA4Ig. Shiraishi T, etal., Am J Transplant. 2002 Mar;2(3):223-8.
106. Cytotoxic T lymphocyte-associated antigen-4 gene polymorphisms confer susceptibility to atopic asthma in Korean children. Sohn MH, etal., Pediatr Pulmonol. 2007 Jun;42(6):542-7.
107. Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Spriewald BM, etal., Ann Rheum Dis. 2005 Mar;64(3):457-61.
108. A suggestive association of fuchs heterochromic cyclitis with cytotoxic T cell antigen 4 gene polymorphism. Spriewald BM, etal., Ophthalmic Res. 2007;39(2):116-20. Epub 2007 Feb 8.
109. Clinical manifestations and analyses of the cytotoxic T-lymphocyte associated-4 gene in two Japanese families with systemic lupus erythematosus. Sugimoto K, etal., Clin Exp Nephrol. 2008 Apr;12(2):149-54. doi: 10.1007/s10157-007-0019-0. Epub 2008 Jan 9.
110. [Effects and mechanism of CD4+ CD25+ T cells on the airway inflammation of asthmatic mice]. Sun K, etal., Zhonghua Jie He He Hu Xi Za Zhi. 2006 Feb;29(2):109-12.
111. Hydrodynamics-based delivery of plasmid DNA encoding CTLA4-Ig prolonged cardiac allograft survival in rats. Takekubo M, etal., J Gene Med. 2008 Mar;10(3):290-7.
112. Involvement of CD28/CTLA4-B7 costimulatory pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr mice. Takiguchi M, etal., J Vet Med Sci. 2000 Jan;62(1):29-36.
113. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. Thio CL, etal., J Virol. 2004 Oct;78(20):11258-62. doi: 10.1128/JVI.78.20.11258-11262.2004.
114. CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Vaidya B, etal., Clin Endocrinol (Oxf). 2003 Jun;58(6):732-5.
115. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Vaidya B, etal., Hum Mol Genet 1999 Jul;8(7):1195-9.
116. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Valenti L, etal., Alcohol Alcohol. 2004 Jul-Aug;39(4):276-80. doi: 10.1093/alcalc/agh047.
117. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Verwaerde C, etal., Gene Ther. 2003 Nov;10(23):1970-81.
118. CTLA-4 exon 1 +49A/G polymorphism is associated with renal involvement in pediatric Henoch-Schonlein purpura. Wang JJ, etal., Pediatr Nephrol. 2012 Nov;27(11):2059-64. doi: 10.1007/s00467-012-2216-7. Epub 2012 Jun 15.
119. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. Wang L, etal., BMC Cancer. 2007 Sep 10;7:173.
120. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Waterhouse P, etal., Science 1995 Nov 10;270(5238):985-8.
121. CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Welsh MM, etal., Cancer Res. 2009 Aug 1;69(15):6158-63. doi: 10.1158/0008-5472.CAN-09-0415. Epub 2009 Jul 21.
122. Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy. Wong CK, etal., J Clin Immunol. 2008 Jan;28(1):36-43. Epub 2007 Nov 17.
123. Reduced function of CD4+25+ regulatory T cell fraction in silicosis patients. Wu P, etal., Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):357-68.
124. [Study on mRNA expression of immune-related genes in patients with allergic dermatitis induced by trichloroethylene]. Xu XY, etal., Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2011 Nov;29(11):816-9.
125. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Yang JC, etal., J Immunother. 2007 Nov-Dec;30(8):825-30.
126. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. Yee LJ, etal., J Infect Dis. 2003 Apr 15;187(8):1264-71. doi: 10.1086/374561. Epub 2003 Apr 2.
127. CTLA4 gene polymorphisms in children and adolescents with autoimmune thyroid diseases. Yesilkaya E, etal., Genet Test. 2008 Sep;12(3):461-4. doi: 10.1089/gte.2008.0053.
128. Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy. Yin X, etal., Thyroid. 2012 Jul;22(7):730-6. doi: 10.1089/thy.2012.0007. Epub 2012 Jun 4.
129. Cytotoxic T lymphocyte antigen 4 gene polymorphism associated with ST-segment elevation acute myocardial infarction. Yip HK, etal., Circ J. 2007 Aug;71(8):1213-8.
130. [The implications of nasal associated lymphoid tissue in development of respiratory allergic diseases in children]. Zakrzewska A, etal., Med Wieku Rozwoj. 2007 Apr-Jun;11(2 Pt 1):129-34.
131. Intraarticular gene delivery of CTLA4-FasL suppresses experimental arthritis. Zhang W, etal., Int Immunol. 2012 Jun;24(6):379-88. doi: 10.1093/intimm/dxs041. Epub 2012 Feb 21.
132. Association of the CTLA4 gene with Graves' disease in the Chinese Han population. Zhao SX, etal., PLoS One. 2010 Mar 23;5(3):e9821. doi: 10.1371/journal.pone.0009821.
133. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Zheng C, etal., Br J Haematol. 2001 Jan;112(1):216-8.
134. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G, etal., Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
135. CTLA4 gene polymorphisms are associated with chronic bronchitis. Zhu G, etal., Eur Respir J. 2009 Sep;34(3):598-604. Epub 2009 Apr 22.
Additional References at PubMed
PMID:7544393   PMID:15814706   PMID:16227984   PMID:17875758   PMID:18522879   PMID:18601859   PMID:18641304   PMID:18665051   PMID:19191906   PMID:21532411   PMID:22325471   PMID:28484017  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2962,318,874 - 62,325,978 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl962,319,312 - 62,324,963 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx970,821,431 - 70,826,972 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0975,937,041 - 75,942,584 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0974,255,613 - 74,261,154 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0967,699,397 - 67,706,068 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl967,699,379 - 67,706,065 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0967,509,236 - 67,515,681 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4959,495,773 - 59,501,300 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1959,642,754 - 59,648,282 (+)NCBI
Celera959,742,231 - 59,747,758 (+)NCBICelera
Cytogenetic Map9q32NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh382203,867,771 - 203,873,965 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl2203,853,888 - 203,873,965 (+)EnsemblGRCh38hg38GRCh38
GRCh372204,732,494 - 204,738,688 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 362204,440,754 - 204,446,928 (+)NCBINCBI36Build 36hg18NCBI36
Build 342204,558,016 - 204,564,189NCBI
Celera2198,487,330 - 198,493,462 (+)NCBICelera
Cytogenetic Map2q33.2NCBI
HuRef2196,579,809 - 196,585,939 (+)NCBIHuRef
CHM1_12204,739,066 - 204,745,196 (+)NCBICHM1_1
T2T-CHM13v2.02204,349,656 - 204,355,847 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39160,948,184 - 60,954,991 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl160,926,159 - 60,954,991 (+)EnsemblGRCm39 Ensembl
GRCm38160,909,025 - 60,915,832 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl160,887,000 - 60,915,832 (+)EnsemblGRCm38mm10GRCm38
MGSCv37160,965,869 - 60,972,674 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36160,853,571 - 60,860,376 (+)NCBIMGSCv36mm8
Celera161,424,040 - 61,430,841 (+)NCBICelera
Cytogenetic Map1C2NCBI
cM Map130.58NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_00495545711,028,698 - 11,073,460 (-)EnsemblChiLan1.0
ChiLan1.0NW_00495545711,028,707 - 11,034,898 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan12B106,487,372 - 106,493,704 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v02B91,054,917 - 91,106,234 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.12B209,239,417 - 209,244,498 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl2B209,239,417 - 209,244,498 (+)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.13712,647,712 - 12,653,874 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl3712,634,563 - 12,653,874 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha3713,530,863 - 13,537,025 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.03712,584,278 - 12,590,425 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl3712,528,644 - 12,590,422 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.13712,541,354 - 12,547,516 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.03712,504,724 - 12,510,894 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.03712,505,745 - 12,511,890 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_024405303160,849,279 - 160,854,996 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936631484,356 - 489,643 (+)EnsemblSpeTri2.0
SpeTri2.0NW_004936631484,356 - 489,643 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl15107,282,927 - 107,289,103 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.115107,283,081 - 107,288,041 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.215118,627,675 - 118,632,732 (+)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.11089,637,176 - 89,644,436 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1089,638,314 - 89,642,344 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_023666040109,742,081 - 109,748,529 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_00462476512,449,205 - 12,454,324 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462476512,449,205 - 12,454,324 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Ctla4
33 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:61
Count of miRNA genes:60
Interacting mature miRNAs:61
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
10054125Srcrt7Stress Responsive Cort QTL 73.330.0011blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)9187073594Rat
1331757Cdexp1CD45RC expression in CD8 T cells QTL 14.3CD8-positive T cell quantity (VT:0008077)blood CD45RC(high) CD8 T cell count to CD45RC(low) CD8 T cell count ratio (CMO:0001990)9102453767509080Rat
631680Cm11Cardiac mass QTL 113.10.00089heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)92043051965430519Rat
70186Niddm26Non-insulin dependent diabetes mellitus QTL 263.87blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)92207116986369743Rat
631643Bp120Blood pressure QTL 12030.004arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)92207120067071200Rat
7207814Bmd91Bone mineral density QTL 913.5femur size trait (VT:1000369)femoral neck cross-sectional area (CMO:0001697)92375414483851531Rat
70218Cm28Cardiac mass QTL 288.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)92526804479271759Rat
724544Uae9Urinary albumin excretion QTL 94.5urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)925268044114175309Rat
731164Uae25Urinary albumin excretion QTL 253.50.0001urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)925661188100929786Rat
1641894Alcrsp12Alcohol response QTL 12response to alcohol trait (VT:0010489)brain neurotensin receptor 1 density (CMO:0002068)92746863972468639Rat
7411656Foco26Food consumption QTL 269.80.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)93253550577535505Rat
7411571Bw138Body weight QTL 13814.30.001body mass (VT:0001259)body weight gain (CMO:0000420)93253550577535505Rat
1598834Memor11Memory QTL 112.5exploratory behavior trait (VT:0010471)average horizontal distance between subject and target during voluntary locomotion in an experimental apparatus (CMO:0002674)93696235977814038Rat
8662828Vetf6Vascular elastic tissue fragility QTL 63.9artery integrity trait (VT:0010639)patent ductus arteriosus score (CMO:0002566)93696235992058970Rat
2290450Scl57Serum cholesterol level QTL 574.15blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)93696235995410867Rat
6903941Pur31Proteinuria QTL 310.036urine total protein amount (VT:0000032)urine protein excretion rate (CMO:0000759)94019418885194188Rat
11353949Bp393Blood pressure QTL 393arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)94019418885194188Rat
61352Bp34Blood pressure QTL 345arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)94249534379271511Rat
10058949Gmadr5Adrenal mass QTL 520.014adrenal gland mass (VT:0010420)both adrenal glands wet weight to body weight ratio (CMO:0002411)94279151387976209Rat
11353951Bp394Blood pressure QTL 394arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)94464992189649921Rat
12879506Pur33Proteinuria QTL 33urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)94464992189649921Rat
11353957Bmd92Bone mineral density QTL 920.01tibia mineral mass (VT:1000283)volumetric bone mineral density (CMO:0001553)94611419991114199Rat
631656Bp108Blood pressure QTL 1085.970.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)94859825193598251Rat
1598849Memor17Memory QTL 172.2exploratory behavior trait (VT:0010471)difference between time of physical contact/close proximity of test subject and social stimulus during sample phase and test phase (CMO:0002678)94996854671098346Rat
2303170Bp332Blood pressure QTL 3323.730.027arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)95584784177026453Rat
2303180Bp333Blood pressure QTL 3330.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)95662771378595166Rat
2303180Bp333Blood pressure QTL 3330.001arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)95662771378595166Rat
2303180Bp333Blood pressure QTL 3330.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)95662771378595166Rat
1578760Cm53Cardiac mass QTL 533.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)956771635101771635Rat
724515Uae16Urinary albumin excretion QTL 168urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)958163035100929646Rat
1578659Tspe1Trichinella spiralis expulsion QTL 14.8parasite quantity (VT:0010441)logarithm of the intestinal adult Trichinella spiralis count (CMO:0002024)96138143465691299Rat
1300134Bp185Blood pressure QTL 1853.73arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)961381434104821652Rat
1581580Uae34Urinary albumin excretion QTL 34urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)96207227596470995Rat
1578757Pur6Proteinuria QTL 63.30.005urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)96207227596470995Rat


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 1 1
Low 3 7 18 22 3 4 7
Below cutoff 14 17 12 12 2 2 46 26 23 4 2


RefSeq Acc Id: ENSRNOT00000088183   ⟹   ENSRNOP00000069885
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl962,319,312 - 62,324,963 (+)Ensembl
Rnor_6.0 Ensembl967,699,515 - 67,705,042 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000091237   ⟹   ENSRNOP00000073071
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl962,319,312 - 62,324,963 (+)Ensembl
Rnor_6.0 Ensembl967,699,379 - 67,706,065 (+)Ensembl
RefSeq Acc Id: NM_031674   ⟹   NP_113862
Rat AssemblyChrPosition (strand)Source
mRatBN7.2962,319,436 - 62,324,963 (+)NCBI
Rnor_6.0967,699,515 - 67,705,042 (+)NCBI
Rnor_5.0967,509,236 - 67,515,681 (+)NCBI
RGSC_v3.4959,495,773 - 59,501,300 (+)RGD
Celera959,742,231 - 59,747,758 (+)RGD
RefSeq Acc Id: XM_006245036   ⟹   XP_006245098
Rat AssemblyChrPosition (strand)Source
mRatBN7.2962,318,874 - 62,325,978 (+)NCBI
Rnor_6.0967,699,397 - 67,706,068 (+)NCBI
Rnor_5.0967,509,236 - 67,515,681 (+)NCBI
RefSeq Acc Id: NP_113862   ⟸   NM_031674
- Peptide Label: precursor
- UniProtKB: Q62859 (UniProtKB/TrEMBL),   A0A096MJE4 (UniProtKB/TrEMBL),   A6IPD6 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006245098   ⟸   XM_006245036
- Peptide Label: isoform X1
- UniProtKB: G3V7D2 (UniProtKB/TrEMBL),   A6IPD7 (UniProtKB/TrEMBL),   Q9Z1A7 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000073071   ⟸   ENSRNOT00000091237
RefSeq Acc Id: ENSRNOP00000069885   ⟸   ENSRNOT00000088183
Protein Domains

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-A0A096MJE4-F1-model_v2 AlphaFold A0A096MJE4 1-223 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:61975 AgrOrtholog
BioCyc Gene G2FUF-27370 BioCyc
Ensembl Genes ENSRNOG00000054129 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000069885 ENTREZGENE
  ENSRNOP00000069885.1 UniProtKB/TrEMBL
  ENSRNOP00000073071.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000088183 ENTREZGENE
  ENSRNOT00000088183.2 UniProtKB/TrEMBL
  ENSRNOT00000091237.2 UniProtKB/TrEMBL
InterPro CTLA4 UniProtKB/TrEMBL
  Ig-like UniProtKB/TrEMBL
  Ig-like_dom_sf UniProtKB/TrEMBL
  Ig-like_fold UniProtKB/TrEMBL
  Ig_sub UniProtKB/TrEMBL
  Ig_V-set UniProtKB/TrEMBL
KEGG Report rno:63835 UniProtKB/TrEMBL
  PTHR11494:SF8 UniProtKB/TrEMBL
Pfam V-set UniProtKB/TrEMBL
PhenoGen Ctla4 PhenoGen
  SM00409 UniProtKB/TrEMBL
Superfamily-SCOP SSF48726 UniProtKB/TrEMBL

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-09-10 Ctla4  cytotoxic T-lymphocyte-associated protein 4  Cd152  CD152 antigen  Symbol and Name updated 1299863 APPROVED
2002-06-10 Cd152  CD152 antigen      Name updated 70584 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_transcript alternatively spliced transcripts lack the exon 3 encoded transmembrane domain 634642